Lineage Cell Therapeutics, Inc. (TLV:LCTX)
Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
498.30
-16.20 (-3.15%)
At close: Mar 13, 2026

Lineage Cell Therapeutics Balance Sheet

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Equivalents
40.7945.7935.4411.3655.74
Short-Term Investments
14.992.020.0546.522.62
Cash & Short-Term Investments
55.7847.8135.4957.8858.36
Cash Growth
16.68%34.69%-38.67%-0.83%40.41%
Accounts Receivable
0.890.640.750.350.84
Other Current Assets
2.492.552.21.832.35
Total Current Assets
59.165138.4460111.55
Net Property, Plant & Equipment
4.74.44.775.674.87
Other Intangible Assets
31.746.5446.5646.6946.82
Goodwill
10.6710.6710.6710.6710.67
Other Long-Term Assets
6.360.610.580.630.63
Total Assets
112.58113.22101.02123.66174.55
Accounts Payable
7.185.446.278.6127.97
Current Portion of Leases
0.851.150.880.950.83
Unearned Revenue
3.337.3910.819.4218.12
Other Current Liabilities
----0.2
Total Current Liabilities
11.3713.9817.9618.9847.12
Long-Term Leases
1.571.362.072.941.97
Other Long-Term Liabilities
56.3120.8718.9729.834.56
Total Long-Term Liabilities
57.8722.2321.0432.7536.53
Total Liabilities
69.2436.213951.7383.65
Common Stock
515.47484.72451.34440.28434.53
Accumulated Other Comprehensive Income
-3.92-2.88-3.07-3.57-5.21
Retained Earnings
-467-403.47-384.86-363.37-337.1
Total Common Shareholders' Equity
44.5578.3863.4273.3492.22
Minority Interest
-1.2-1.37-1.4-1.4-1.32
Shareholders' Equity
43.3577.0162.0271.9490.9
Total Liabilities & Equity
112.58113.22101.02123.66174.55
Total Debt
2.422.512.953.92.8
Net Cash (Debt)
53.3645.2932.5453.9855.56
Net Cash Growth
17.82%39.19%-39.72%-2.84%45.21%
Net Cash Per Share
0.230.230.190.320.34
Book Value
44.5578.3863.4273.3492.22
Book Value Per Share
0.190.390.370.430.56
Tangible Book Value
2.1821.176.1915.9834.73
Tangible Book Value Per Share
0.010.110.040.090.21
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.